Table 2 Antibody distribution in 169 patients with Crohn’s disease (CD), 102 patients with ulcerative colitis (UC), and 225 controls
CD | UC | controls | ||
|---|---|---|---|---|
All CD patients (n = 169) | ASCA negative CD patients (n = 109) | (n = 102) | (n = 225) | |
Anti-GP2 IgA, (%) | 22 (13.0) | 9 (8.2) | 2 (2.0) | 3 (1.3) |
Anti-GP2 IgG, (%) | 48 (28.4) | 25 (22.9) | 8 (7.8) | 6 (2.7) |
Anti-GP2 IgA and/or IgG, (%) | 51 (30.2) | 26 (23.9) | 9 (8.8) | 9 (4.0) |
PAB > = 1/20, (%) | 74 (43.8) | 45 (41.3) | 24 (23.5) | nd |
PAB > = 1/40, (%) | 65 (38.5) | 38 (34.9) | 21 (20.6) | nd |
ASCA IgA, (%) | 39 (23.1) | - | 3 (2.9) | 2 (0.9) |
ASCA IgG, (%) | 48 (28.4) | - | 5 (4.9) | 7 (3.1) |
ASCA IgA and/or IgG, (%) | 60 (35.5) | - | 7 (6.9) | 8 (3.5) |
ASCA and/or anti-GP2, (%) | 86 (50.9) | - | 15 (14.7) | 16 (7.1) |
Number of positive antibodies detected by ELISA | ||||
0 | 83 (49.1) | 83 (76.1) | 87 (85.3) | 208 (92.4) |
1 | 40 (23.7) | 18 (16.5) | 12 (11.8) | 13 (5.8) |
2 | 28 (16.6) | 8 (7.3) | 3 (2.9) | 4 (1.8) |
3 | 11 (6.5) | - | 0 (0.0) | 0 (0.0) |
4 | 7 (4.1) | - | 0 (0.0) | 0 (0.0) |